Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
studyfinds5d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
BMJ5d
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
Critical Flaws: New Alzheimer’s Drug Could Actually Be a Safety Risk
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
News Medical on MSN5d
Questions over safety and effectiveness of new Alzheimer's drug
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with ...
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
McKnight's Long-Term Care News5d
Journalists question safety and effectiveness of new Alzheimer’s drug
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
Japan approves new drug 'donanemab' to treat Alzheimer's disease
Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.
Nasdaq5d
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab
(RTTNews) - An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked to multiple patient deaths during trials ...